Abstract
Cannabidiol (CBD), which is nonintoxicating pharmacologically relevant constituents of Cannabis, demonstrates several beneficial effects. It has been found to have antioxidative, anti-inflammatory, and neuroprotective effects. As the medicinal use of CBD is gaining popularity for treatment of various disorders, the recent flare-up of largely unproven and unregulated cannabis-based preparations on medical therapeutics may have its greatest impact in the field of neurology. Currently, as lot of clinical trials are underway, CBD demonstrates remarkable potential to become a supplemental therapy in various neurological conditions. It has shown promise in the treatment of neurological disorders such as anxiety, chronic pain, trigeminal neuralgia, epilepsy, and essential tremors as well as psychiatric disorders. While recent FDA-approved prescription drugs have demonstrated safety, efficacy, and consistency enough for regulatory approval in spasticity in multiple sclerosis (MS) and in Dravet and Lennox-Gastaut Syndromes (LGS), many therapeutic challenges still remain. In the current review, the authors have shed light on the application of CBD in the management and treatment of various neurological disorders.
Similar content being viewed by others
References
Volkow ND, Compton WM, Weiss SR (2014) Adverse health effects of marijuana use. N Engl J Med 371(9):878–879. https://doi.org/10.1056/NEJMc1407928
Volkow ND, Swanson JM, Evins AE, DeLisi LE, Meier MH, Gonzalez R, Bloomfield MA, Curran HV, Baler R (2016) Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. JAMA Psychiatry 73(3):292–297. https://doi.org/10.1001/jamapsychiatry.2015.3278
Jamil M, Zafar A, Adeel Faizi S, Zawar I (2016) Stroke from vasospasm due to marijuana use: can cannabis synergistically with other medications trigger cerebral vasospasm? Case Rep Neurol Med 2016:5313795–5313794. https://doi.org/10.1155/2016/5313795
Bergamaschi MM, Queiroz RH, Zuardi AW, Crippa JA (2011) Safety and side effects of cannabidiol, a cannabis sativa constituent. Curr Drug Saf 6(4):237–249. https://doi.org/10.2174/157488611798280924
Grotenhermen F, Müller-Vahl K (2016) Cannabis und cannabinoide in der medizin: fakten und ausblick. Suchttherapie 17(02):71–76. https://doi.org/10.1055/s-0042-100702
Hampson AJ, Grimaldi M, Axelrod J, Wink D (1998) Cannabidiol and (−)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A 95(14):8268–8273. https://doi.org/10.1073/pnas.95.14.8268
Oláh A, Tóth BI, Borbíró I, Sugawara K, Szöllõsi AG, Czifra G, Pál B, Ambrus L, Kloepper J, Camera E, Ludovici M, Picardo M, Voets T, Zouboulis CC, Paus R, Bíró T (2014) Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. J Clin Investig 124(9):3713–3724. https://doi.org/10.1172/jci64628
Mikuriya TH (1969) Marijuana in medicine: past, present and future. Calif Med 110(1):34–40
Pisanti S, Malfitano AM, Ciaglia E, Lamberti A, Ranieri R, Cuomo G, Abate M, Faggiana G, Proto MC, Fiore D, Laezza C, Bifulco M (2017) Cannabidiol: state of the art and new challenges for therapeutic applications. Pharmacol Ther 175:133–150. https://doi.org/10.1016/j.pharmthera.2017.02.041
Mechoulam R, Shvo Y (1963) Hashish—I: the structure of cannabidiol. Tetrahedron 19(12):2073–2078
Scuderi C, Filippis DD, Iuvone T, Blasio A, Steardo A, Esposito G (2009) Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders. Phytother Res 23(5):597–602. https://doi.org/10.1002/ptr.2625
Ramer R, Heinemann K, Merkord J, Rohde H, Salamon A, Linnebacher M, Hinz B (2013) COX-2 and PPAR-gamma confer cannabidiol-induced apoptosis of human lung cancer cells. Mol Cancer Ther 12(1):69–82. https://doi.org/10.1158/1535-7163.MCT-12-0335
Pertwee RG (1997) Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74(2):129–180
Lunn CA, Reich EP, Bober L (2006) Targeting the CB2 receptor for immune modulation. Expert Opin Ther Targets 10(5):653–663. https://doi.org/10.1517/14728222.10.5.653
Veronesi B, Oortgiesen M (2006) The TRPV1 receptor: target of toxicants and therapeutics. Toxicol Sci 89(1):1–3. https://doi.org/10.1093/toxsci/kfj034
Pazos MR, Mohammed N, Lafuente H, Santos M, Martinez-Pinilla E, Moreno E, Valdizan E, Romero J, Pazos A, Franco R, Hillard CJ, Alvarez FJ, Martinez-Orgado J (2013) Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: role of 5HT(1A) and CB2 receptors. Neuropharmacology 71:282–291. https://doi.org/10.1016/j.neuropharm.2013.03.027
Rock EM, Limebeer CL, Mechoulam R, Piomelli D, Parker LA (2008) The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat. Psychopharmacology 196(3):389–395. https://doi.org/10.1007/s00213-007-0970-1
Soares Vde P, Campos AC, Bortoli VC, Zangrossi H Jr, Guimaraes FS, Zuardi AW (2010) Intra-dorsal periaqueductal gray administration of cannabidiol blocks panic-like response by activating 5-HT1A receptors. Behav Brain Res 213(2):225–229. https://doi.org/10.1016/j.bbr.2010.05.004
Chen JW, Borgelt LM, Blackmer AB (2019) Cannabidiol: a new hope for patients with Dravet or Lennox-Gastaut syndromes. Ann Pharmacother 53(6):603–611. https://doi.org/10.1177/1060028018822124
Samara E, Bialer M, Harvey DJ (1990) Pharmacokinetics of urinary metabolites of cannabidiol in the dog. Biopharm Drug Dispos 11(9):785–795
Wang T, Collet JP, Shapiro S, Ware MA (2008) Adverse effects of medical cannabinoids: a systematic review. CMAJ 178(13):1669–1678. https://doi.org/10.1503/cmaj.071178
Mead A (2016) The legal and regulatory status of cannabidiol (CBD). Planta Med 82(05). https://doi.org/10.1055/s-0036-1578585
Mead A (2017) The legal status of cannabis (marijuana) and cannabidiol (CBD) under U.S. law. Epilepsy Behav 70(Pt B):288–291. https://doi.org/10.1016/j.yebeh.2016.11.021
Urits I, Borchart M, Hasegawa M, Kochanski J, Orhurhu V, Viswanath O (2019) An update of current cannabis-based pharmaceuticals in pain medicine. Pain Ther 8(1):41–51. https://doi.org/10.1007/s40122-019-0114-4
Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D (2007) Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain 133(1–3):210–220. https://doi.org/10.1016/j.pain.2007.08.028
CADTH rapid response reports (2016) Cannabinoid buccal spray for chronic non-cancer or neuropathic pain: a review of clinical effectiveness, safety, and guidelines. In: CADTH Rapid Response Reports. Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)
Blake DR, Robson P, Ho M, Jubb RW, McCabe CS (2006) Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford) 45(1):50–52. https://doi.org/10.1093/rheumatology/kei183
Arjmand S, Vaziri Z, Behzadi M, Abbassian H, Stephens GJ, Shabani M (2015) Cannabinoids and tremor induced by motor-related disorders: friend or foe? Neurotherapeutics 12(4):778–787. https://doi.org/10.1007/s13311-015-0367-5
Ibeas Bih C, Chen T, Nunn AV, Bazelot M, Dallas M, Whalley BJ (2015) Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics 12(4):699–730. https://doi.org/10.1007/s13311-015-0377-3
Abbassian H, Whalley BJ, Sheibani V, Shabani M (2016) Cannabinoid type 1 receptor antagonism ameliorates harmaline-induced essential tremor in rat. Br J Pharmacol 173(22):3196–3207. https://doi.org/10.1111/bph.13581
Kolasiewicz W, Kuter K, Wardas J, Ossowska K (2009) Role of the metabotropic glutamate receptor subtype 1 in the harmaline-induced tremor in rats. J Neural Transm (Vienna) 116(9):1059–1063. https://doi.org/10.1007/s00702-009-0254-5
Handforth A (2012) Harmaline tremor: underlying mechanisms in a potential animal model of essential tremor. Tremor Other Hyperkinet Mov (N Y) 2. https://doi.org/10.7916/D8TD9W2P
Iuvone T, Esposito G, De Filippis D, Scuderi C, Steardo L (2009) Cannabidiol: a promising drug for neurodegenerative disorders? CNS Neurosci Ther 15(1):65–75. https://doi.org/10.1111/j.1755-5949.2008.00065.x
Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernandez-Ruiz J (2005) Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol Dis 19(1–2):96–107. https://doi.org/10.1016/j.nbd.2004.11.009
Devinsky O, Marsh E, Friedman D (2016) Cannabidiol in patients with treatment-resistant epilepsy - Authors' reply. Lancet Neurol 15(6):545–546. https://doi.org/10.1016/S1474-4422(16)00120-4
Laurie K Mischley N (2019) Cannabis and Parkinson's disease tremor: a natural history study. https://clinicaltrials.gov/ct2/show/NCT02028858
Blessing EM, Steenkamp MM, Manzanares J, Marmar CR (2015) Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics 12(4):825–836. https://doi.org/10.1007/s13311-015-0387-1
Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG (1982) Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology 76(3):245–250
Zuardi AW, Cosme RA, Graeff FG, Guimaraes FS (1993) Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol 7(1 Suppl):82–88. https://doi.org/10.1177/026988119300700112
McDonough P, McKenna JP, McCreary C, Downer EJ (2014) Neuropathic orofacial pain: cannabinoids as a therapeutic avenue. Int J Biochem Cell Biol 55:72–78. https://doi.org/10.1016/j.biocel.2014.08.007
Chagas MH, Eckeli AL, Zuardi AW, Pena-Pereira MA, Sobreira-Neto MA, Sobreira ET, Camilo MR, Bergamaschi MM, Schenck CH, Hallak JE, Tumas V, Crippa JA (2014) Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series. J Clin Pharm Ther 39(5):564–566. https://doi.org/10.1111/jcpt.12179
Consroe P, Musty R, Rein J, Tillery W, Pertwee R (1997) The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 38(1):44–48. https://doi.org/10.1159/000112901
Elliott J, McCoy B, Clifford T, Potter BK, Skidmore B, Wells GA, Coyle D (2019) Cost-effectiveness of cannabinoids for pediatric drug-resistant epilepsy: protocol for a systematic review of economic evaluations. Syst Rev 8(1):75. https://doi.org/10.1186/s13643-019-0990-z
Liang YC, Huang CC, Hsu KS (2007) The synthetic cannabinoids attenuate allodynia and hyperalgesia in a rat model of trigeminal neuropathic pain. Neuropharmacology 53(1):169–177. https://doi.org/10.1016/j.neuropharm.2007.04.019
Harold Merskey D (1994) Classification of chronic pain: description of chronic pain syndromes and definitions of pain terms, 2nd edn. IASP PRESS, Seattle
Mondello E, Quattrone D, Cardia L, Bova G, Mallamace R, Barbagallo AA, Mondello C, Mannucci C, Di Pietro M, Arcoraci V, Calapai G (2018) Cannabinoids and spinal cord stimulation for the treatment of failed back surgery syndrome refractory pain. J Pain Res 11:1761–1767. https://doi.org/10.2147/JPR.S166617
Peul WC, van Houwelingen HC, van den Hout WB, Brand R, Eekhof JA, Tans JT, Thomeer RT, Koes BW, Leiden-The Hague Spine Intervention Prognostic Study G (2007) Surgery versus prolonged conservative treatment for sciatica. N Engl J Med 356(22):2245–2256. https://doi.org/10.1056/NEJMoa064039
Compston A, Coles A (2002) Multiple sclerosis. Lancet 359(9313):1221–1231. https://doi.org/10.1016/S0140-6736(02)08220-X
Perras C (2005) Sativex for the management of multiple sclerosis symptoms. Issues Emerg Health Technol 72:1–4
Koppel BS, Brust JC, Fife T, Bronstein J, Youssof S, Gronseth G, Gloss D (2014) Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 82(17):1556–1563. https://doi.org/10.1212/WNL.0000000000000363
Consroe P, Kennedy K, Schram K (1991) Assay of plasma cannabidiol by capillary gas chromatography/ion trap mass spectroscopy following high-dose repeated daily oral administration in humans. Pharmacol Biochem Behav 40(3):517–522
Hussain SA, Zhou R, Jacobson C, Weng J, Cheng E, Lay J, Hung P, Lerner JT, Sankar R (2015) Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: a potential role for infantile spasms and Lennox-Gastaut syndrome. Epilepsy Behav 47:138–141. https://doi.org/10.1016/j.yebeh.2015.04.009
Kurz R, Blaas K (2010) Use of dronabinol (delta-9-THC) in autism: a prospective single-case-study with an early infantile autistic child. Cannabinoids 5(4):4–6
Fernandez-Lopez D, Lizasoain I, Moro MA, Martinez-Orgado J (2013) Cannabinoids: well-suited candidates for the treatment of perinatal brain injury. Brain Sci 3(3):1043–1059. https://doi.org/10.3390/brainsci3031043
Fisher T, Golan H, Schiby G, PriChen S, Smoum R, Moshe I, Peshes-Yaloz N, Castiel A, Waldman D, Gallily R, Mechoulam R, Toren A (2016) In vitro and in vivo efficacy of non-psychoactive cannabidiol in neuroblastoma. Curr Oncol 23(2):S15–S22. https://doi.org/10.3747/co.23.2893
Burns HD, Van Laere K, Sanabria-Bohorquez S, Hamill TG, Bormans G, Eng WS, Gibson R, Ryan C, Connolly B, Patel S, Krause S, Vanko A, Van Hecken A, Dupont P, De Lepeleire I, Rothenberg P, Stoch SA, Cote J, Hagmann WK, Jewell JP, Lin LS, Liu P, Goulet MT, Gottesdiener K, Wagner JA, de Hoon J, Mortelmans L, Fong TM, Hargreaves RJ (2007) [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc Natl Acad Sci U S A 104(23):9800–9805. https://doi.org/10.1073/pnas.0703472104
Hayatbakhsh MR, Najman JM, Jamrozik K, Mamun AA, Alati R, Bor W (2007) Cannabis and anxiety and depression in young adults: a large prospective study. J Am Acad Child Adolesc Psychiatry 46(3):408–417. https://doi.org/10.1097/chi.0b013e31802dc54d
Fontes MA, Bolla KI, Cunha PJ, Almeida PP, Jungerman F, Laranjeira RR, Bressan RA, Lacerda AL (2011) Cannabis use before age 15 and subsequent executive functioning. Br J Psychiatry 198(6):442–447. https://doi.org/10.1192/bjp.bp.110.077479
Batalla A, Janssen H, Gangadin SS, Bossong MG (2019) The potential of Cannabidiol as a treatment for psychosis and addiction: who benefits Most? A systematic review. J Clin Med 8(7). https://doi.org/10.3390/jcm8071058
Zuardi AW, Crippa JA, Hallak JE, Bhattacharyya S, Atakan Z, Martin-Santos R, McGuire PK, Guimaraes FS (2012) A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation. Curr Pharm Des 18(32):5131–5140. https://doi.org/10.2174/138161212802884681
Walther S, Halpern M (2010) Cannabinoids and dementia: a review of clinical and preclinical data. Pharmaceuticals 3(8):2689–2708. https://doi.org/10.3390/ph3082689
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.
Ethical approval and informed consent
This is a review which did not include any human research subject participation. Therefore, no informed consent or ethical approval was required for this review.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Fiani, B., Sarhadi, K.J., Soula, M. et al. Current application of cannabidiol (CBD) in the management and treatment of neurological disorders. Neurol Sci 41, 3085–3098 (2020). https://doi.org/10.1007/s10072-020-04514-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-020-04514-2